This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Solid Biosciences’s 8K filing here.
About Solid Biosciences
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Recommended Stories
- Five stocks we like better than Solid Biosciences
- How to Most Effectively Use the MarketBeat Earnings Screener
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- What is a Secondary Public Offering? What Investors Need to Know
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Buy P&G Now, Before It Sets A New All-Time High
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
